Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin
Phase of Trial: Phase IV
Latest Information Update: 15 Jun 2019
Price : $35 *
At a glance
- Drugs Botulinum-antitoxin (Primary)
- Indications Botulism
- Focus Adverse reactions
- Sponsors Cangene Corporation
- 15 Jun 2019 Results published in the Clinical Infectious Diseases
- 24 Jan 2018 Status changed from recruiting to completed.
- 04 Apr 2016 Planned End Date changed from 1 Apr 2018 to 1 Dec 2017 as reported by ClinicalTrials.gov.